期刊文献+

小剂量MAE方案治疗难治与复发急性白血病 被引量:2

Chemotherapy combined with small dose MAE regimen for patients with relapsed or refractory acute myeloid leukemia
下载PDF
导出
摘要 目的:探讨小剂量米托蒽醌(MTZ)、阿糖胞苷(Arc)联合依托泊甙(VP-16)治疗难治与复发急性白血病的疗效及毒副作用。方法:难治与复发急性白血病52例,应用小剂量MAE方案化疗,完全缓解后应用中剂量阿糖胞苷或预激方案巩固。结果:22例急性非淋巴细胞白血病中,10例(45.5%)达完全缓解(CR),2例(9.1%)部分缓解(PR),总有效率为54.5%;30例急性淋巴细胞白血病中,9例(30.0%)CR,2例(6.6%)PR,总有效率为36.6%。毒副作用主要是骨髓抑制、恶心、呕吐。结论:小剂量MAE方案治疗难治与复发急性白血病的疗效较好,毒副作用较轻。 Objective:To study the effect and safety of small dose mitoxantron, cytarabine combined with etoposide (MAE) for recurrent or refractory acute leukemia. Methods: All the 52 patients were reliably diagnosed recurrent or refractory acute leukemia hospitalized in our department from 2004 to 2006 . The regimen, small dose MAE, consisted of mitoxantron 3 - 4mg/m2/day, on days 1 - 3, cytarabine 80 mg/m2/day, on days 1- 5, and etoposide 100 mg/days,on days 1 -3 ,all by intravenous continuous infusion. After achievement of CR, the patients received small dose MAE, middle dose Ara - C, and the granulocyte colony - stimulating factor priming regimen simultaneously for consolidation. Results: Ten of the 22 (45.5 % ) acute myeloid leukemia (AML) patients achieved complete remission (CR) and 2 of them (9.1%) achieved part remission (PR), 9 of the 30 (30.0%) lymphocytic leukemia (ALL) achieved CR and 2 of them (6.6%) achieved PR, the effective rate of the small dose MAE regimen for AML was 54.5% and for ALL was 36.6% , respectively. The main toxicities were myelosuppression, nausea and vomiting. Conclusion: The small dose MAE regimen is effective and well tolerated in remission induction and consolidation therapy for refractory and relapsed acute leukemia patients.
出处 《现代肿瘤医学》 CAS 2008年第1期102-104,共3页 Journal of Modern Oncology
关键词 难治与复发急性白血病 小剂量MAE方案 疗效 毒副作用 acute leukemia MAE regimen effect toxicity
  • 相关文献

参考文献8

  • 1张之南.血液学诊断及疗效标准[M].北京:科学出版社,1998.171-194.
  • 2王振义,陈秋生.急性白血病免疫治疗的研究现况和前景[J].中国实验血液学杂志,2005,13(2):169-173. 被引量:12
  • 3Michieli M, Damiani D, Ermacora A, etal. P - glycoprotein,lung resistance - related protein and multidrug resistance associated protein in denovo acute non -lymphocytic leukaemia: biological and clinical implication [ J ]. Br J Heamatol, 1999,104:328 - 335.
  • 4Stanisic S,Kalaycio M. Treatment of refractory and relapsed acute myelogenous leukemia[ J ]. Expert Rev Anticancer Ther, 2002,2 : 287-295.
  • 5Bezwoda WR, Bermasconi C, Hutchinson RM, et al. Mitoxantrone for refractory and relapsed acute leukemia[ J ]. Cancer, 1990,66: 418.
  • 6Peter JR,Cathryn R,David RH ,et al. A phase II study of high dose Ara-c and mitoxantrone for the treatment of relapse or refractory adult acute lymphoblasic leukemia[J]. Leuk Res,2000,24:183-187.
  • 7崔中光,赵洪国,汪洪毅,李广伦.MAE方案治疗难治性急性髓性白血病效果观察[J].青岛大学医学院学报,2001,37(4):345-345. 被引量:1
  • 8Je HL, Seong JC, Jung HL,et al. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia [ J ]. Leukemia Res, 2006,30:204 - 210.

二级参考文献31

  • 1[2]Solary E, Wity B, Caillot D, et al. Combination of quienie as apotential reversing agaent with mitoxantrone and cytoarabine forthe treatment of acute leukemia[J]. Blood, 1996,88:1198
  • 2[3]Feldman EF, Alberts DS, Arlin Z , et al. Phase Ⅰ clinical andpharmacokinetic evaluation of high-dose mitoxantrone in comination with cytoarabine in patient with acute leukemia[J]. J ClinOncology, 1993,11: 2002
  • 3[4]Bezwoda WR, Bermasconi C , Hutchinson RM, et al. Mitoxantrone for refractory and relapsed acute leukemia[J]. Cancer,1990,66:418
  • 4王建祥.急性髓系白血病的化疗[A]..第八次全国血液学学术会议论文汇编[C].北京,2004.第31页.
  • 5Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.Expert Opin Biol Ther, 2001; 1: 893 -901.
  • 6Leopold LH, Berger MS, Feingold J. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. Clin Lymphoma, 2002; 2 ( Suppl 1 ): S29- S34.
  • 7Tsimberidou A, Estey F, Cortes J, et al. Gemtuzumab, fiudarabine, cytarbine and cyclosporine in patients with newly newly diagnosed acute myelogenous leukemin or high-risk myelodysplastic syndrome. Cancer, 2003; 97:1481 - 1487.
  • 8LoCoco F, Cimino G, Breccia M, et al. Gentuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 2004; 104: 1995 - 1999.
  • 9Lundin J, Kimby E, Bjorkholm M, et al. Phase Ⅱ trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campth1H) as first line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 2002; 100: 768 - 773.
  • 10Hillmen P. Advancing therapy for chronic lymphocytic leukemia -the role of rituximab. Semin Oncol, 2004; 31 (Suppl 2): 22 -26.

共引文献18

同被引文献10

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部